Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Neuroscientific Biopharmaceuticals Ltd. ( (AU:NSB) ) is now available.
NeuroScientific Biopharmaceuticals Ltd announced promising results from early studies of their StemSmart MSC therapy in renal transplantation. The therapy showed potential in preventing and treating graft failure and rejection, with positive outcomes in patients facing acute renal rejection. The studies demonstrated the therapy’s safety and tolerability, suggesting it could mitigate kidney damage associated with transplantation, representing a significant advancement for deceased-donor renal transplants.
More about Neuroscientific Biopharmaceuticals Ltd.
NeuroScientific Biopharmaceuticals Ltd is a company operating in the biopharmaceutical industry, focusing on developing therapies for immune-inflammatory disorders. Their primary product, StemSmart MSC, is aimed at addressing conditions such as Crohn’s Disease, kidney transplants, lung disorders, and GvHD, with a significant market focus on organ transplant immuno-suppressants.
Average Trading Volume: 615,863
Technical Sentiment Signal: Buy
Current Market Cap: A$61.53M
See more data about NSB stock on TipRanks’ Stock Analysis page.